{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:13:51Z","timestamp":1772820831344,"version":"3.50.1"},"reference-count":111,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019266","name":"GlaxoSmithKline Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022795","name":"Hamilton Health Sciences Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.clml.2023.01.016","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T12:58:19Z","timestamp":1675429099000},"page":"340-354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium"],"prefix":"10.1016","volume":"23","author":[{"given":"Julie","family":"C\u00f4t\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Kotb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra J.","family":"Bergstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hira S.","family":"Mian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibraheem","family":"Othman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha L.","family":"Louzada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.01.016_bib0001","unstructured":"Surveillance, epidemiology and end results (SEER) Cancer Stat Facts: Myeloma. National Cancer Institute. Bethesda, MD. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html Accessed: February 8, 2022."},{"key":"10.1016\/j.clml.2023.01.016_bib0002","unstructured":"American Society of Clinical Oncology (ASCO). ASCO Guidelines Methodology Manual. Available at: https:\/\/www.asco.org\/sites\/new-www.asco.org\/files\/content-files\/practice-and-guidelines\/documents\/2019-Guidelines-Methodology-Manual.pdf. Accessed: March 31, 2022."},{"issue":"1","key":"10.1016\/j.clml.2023.01.016_bib0003","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgo.2019.05.014","article-title":"Autologous stem cell transplant in older patients (age\u00a0\u2265\u00a065) with newly diagnosed multiple myeloma: A systematic review and meta-analysis","volume":"11","author":"Mian","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.01.016_bib0004","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3324\/haematol.2020.262360","article-title":"Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial","volume":"107","author":"Pawlyn","year":"2022","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.clml.2023.01.016_bib0005","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1002\/cncr.33171","article-title":"Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma","volume":"126","author":"Munshi","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2023.01.016_bib0006","unstructured":"Kumar SK, Moreau P, Bahlis NJ, et\u00a0al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 Maia Study. ASH 2022 abstract 4559. Available at: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Paper163335.html. Accessed: November 15, 2022."},{"issue":"3","key":"10.1016\/j.clml.2023.01.016_bib0007","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clml.2023.01.016_bib0008","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.6004\/jnccn.2019.0049","article-title":"NCCN guidelines insights: multiple myeloma, Version 1.2020","volume":"17","author":"Kumar","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"14","key":"10.1016\/j.clml.2023.01.016_bib0009","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2023.01.016_bib0010","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ajh.25797","article-title":"Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75\u2009years","volume":"95","author":"Belotti","year":"2020","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2023.01.016_bib0011","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jgo.2018.05.015","article-title":"Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant","volume":"10","author":"Rosko","year":"2019","journal-title":"J Geriatr Oncol"},{"issue":"22","key":"10.1016\/j.clml.2023.01.016_bib0012","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1200\/JCO.19.02809","article-title":"Defining undertreatment and overtreatment in older adults with cancer: a scoping literature review","volume":"38","author":"DuMontier","year":"2020","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.clml.2023.01.016_bib0013","doi-asserted-by":"crossref","first-page":"pe24","DOI":"10.1126\/sageke.2005.31.pe24","article-title":"From bedside to bench: research agenda for frailty","volume":"2005","author":"Fried","year":"2005","journal-title":"Sci Aging Knowledge Environ"},{"issue":"19","key":"10.1016\/j.clml.2023.01.016_bib0014","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1200\/JCO.21.00089","article-title":"Geriatric assessment and management in cancer","volume":"39","author":"Rostoft","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2023.01.016_bib0015","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamaoncol.2019.4728","article-title":"Communication with older patients with cancer using geriatric assessment: a cluster-randomized clinical trial from the National Cancer Institute Community Oncology Research Program","volume":"6","author":"Mohile","year":"2020","journal-title":"JAMA Oncology"},{"issue":"22","key":"10.1016\/j.clml.2023.01.016_bib0016","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.clml.2023.01.016_bib0017","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.01.016_bib0018","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2023.01.016_bib0019","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/s41375-021-01247-9","article-title":"External validation of the FIRST trial's simplified frailty score in a population-based cohort","volume":"35","author":"Mian","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2023.01.016_bib0020","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.clml.2023.01.016_bib0021","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ajh.24532","article-title":"N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma","volume":"91","author":"Milani","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2023.01.016_bib0022","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2019000758","article-title":"Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.01.016_bib0023","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41408-022-00779-2","article-title":"The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2023.01.016_bib0024","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-126207","article-title":"Frailty-adjusted therapy in transplant non-eligible patients with newly diagnosed multiple myeloma (FiTNEss): a UK Myeloma Research Alliance Study, Myeloma XIV","volume":"134","author":"Cairns","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.01.016_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/asheducation-2018.1.88","article-title":"Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist","volume":"2018","author":"Wildes","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"10.1016\/j.clml.2023.01.016_bib0026","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials","volume":"16","year":"1998","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2023.01.016_bib0027","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1182\/blood-2005-04-1588","article-title":"Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy","volume":"107","author":"Facon","year":"2006","journal-title":"Blood"},{"issue":"9513","key":"10.1016\/j.clml.2023.01.016_bib0028","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clml.2023.01.016_bib0029","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2023.01.016_bib0030","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9594","key":"10.1016\/j.clml.2023.01.016_bib0031","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clml.2023.01.016_bib0032","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2023.01.016_bib0033","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma","volume":"31","author":"San Miguel","year":"2013","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2023.01.016_bib0034","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.01.016_bib0035","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.clml.2023.01.016_bib0036","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2010-02-271676","article-title":"Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma","volume":"115","author":"Reeder","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.01.016_bib0037","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/bmt.2014.288","article-title":"CyBorD induction therapy in clinical practice","volume":"50","author":"Areethamsirikul","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.clml.2023.01.016_bib0038","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2023.01.016_bib0039","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.clml.2023.01.016_bib0040","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2016.66.7295","article-title":"Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, Phase III FIRST Trial","volume":"34","author":"Hulin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10068","key":"10.1016\/j.clml.2023.01.016_bib0041","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clml.2023.01.016_bib0042","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2023.01.016_bib0043","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O'Donnell","year":"2018","journal-title":"Br J Haematol"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2023.01.016_bib0044","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-128000","article-title":"Updated results of a phase 2 study of modified lenalidomide, bortezomib, and dexamethasone (RVd-lite) in transplant-ineligible multiple myeloma","volume":"134","author":"O'Donnell","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.01.016_bib0045","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/bjh.17350","article-title":"Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database","volume":"193","author":"Jimenez-Zepeda","year":"2021","journal-title":"Br J Haematol"},{"issue":"supplement","key":"10.1016\/j.clml.2023.01.016_bib0046","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1016\/S2152-2650(22)00531-6","article-title":"P-201: Outcomes of transplant-ineligible myeloma patients using bortezomib\/lenalidomide containing regimens in the real world: a report from the Canadian Myeloma Research Group Database","volume":"22","author":"Kaedbey","year":"2022","journal-title":"Clin Lymphoma Myeloma and Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2023.01.016_bib0047","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"issue":"10218","key":"10.1016\/j.clml.2023.01.016_bib0048","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clml.2023.01.016_bib0049","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.15806","article-title":"Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study","volume":"185","author":"Yimer","year":"2019","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.clml.2023.01.016_bib0050","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1080\/10428194.2022.2076847","article-title":"Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study","volume":"63","author":"Yimer","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"10.1016\/j.clml.2023.01.016_bib0051","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.01.016_bib0052","unstructured":"Kumar SK, Moreau P, Bahlis NJ, et\u00a0al. daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 Maia Study. ASH 2022 abstract 4559. Available at: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Paper163335.html. Accessed: November 15, 2022."},{"issue":"3","key":"10.1016\/j.clml.2023.01.016_bib0053","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.20.01370","article-title":"Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the Phase III MAIA trial","volume":"39","author":"Perrot","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clml.2023.01.016_bib0054","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8056","article-title":"Bortezomib, lenalidomide, and dexamethasone (VRd) \u00b1 daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: a multicenter, randomized, phase III study (CEPHEUS)","volume":"37","author":"Zweegman","year":"2019","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.clml.2023.01.016_bib0055","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood.2020009507","article-title":"Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.01.016_bib0056","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2023.01.016_bib0057","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.clml.2021.06.005","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE","volume":"21","author":"Mateos","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.01.016_bib0058","unstructured":"Moreau P, Facon T, Usmani S, et\u00a0al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in transplant-ineligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): clinical assessment of key subgroups of the phase 3 Maia Study. ASH 2022 abstract 3245. Available at: https:\/\/ash.confex.com\/ash\/2022\/webprogram\/Paper163494.html. Accessed: November 15, 2022."},{"issue":"7","key":"10.1016\/j.clml.2023.01.016_bib0059","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/j.clml.2020.01.017","article-title":"Myeloma Canada Research Network Consensus Guideline Consortium. Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium","volume":"20","author":"Bergstrom","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.clml.2023.01.016_bib0060","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","article-title":"Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine","volume":"47","author":"Bradwell","year":"2001","journal-title":"Clin Chem"},{"issue":"9","key":"10.1016\/j.clml.2023.01.016_bib0061","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1182\/blood.V97.9.2900","article-title":"Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma","volume":"97","author":"Drayson","year":"2001","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2023.01.016_bib0062","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clml.2023.01.016_bib0063","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J"},{"issue":"S1","key":"10.1016\/j.clml.2023.01.016_bib0064","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.5045\/br.2020.S008","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"55","author":"Lee","year":"2020","journal-title":"Blood Res"},{"issue":"1","key":"10.1016\/j.clml.2023.01.016_bib0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.clml.2023.01.016_bib0066","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.clml.2023.01.016_bib0067","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2023.01.016_bib0068","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.leu.2405016","article-title":"ASH\/FDA panel on clinical endpoints in multiple myeloma. Clinically relevant end points and new drug approvals for myeloma","volume":"22","author":"Anderson","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2023.01.016_bib0069","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.clml.2021.07.028","article-title":"Management of myeloma manifestations and complications: the cornerstone of supportive care: recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium","volume":"22","author":"LeBlanc","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.01.016_bib0070","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.637593","article-title":"Prevalence of chemotherapy-induced peripheral neuropathy in multiple myeloma patients and its impact on quality of life: a single center cross-sectional study","volume":"12","author":"Selvy","year":"2021","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.clml.2023.01.016_bib0071","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3324\/haematol.2015.124347","article-title":"Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial","volume":"100","author":"Merz","year":"2015","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2023.01.016_bib0072","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2023.01.016_bib0073","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3324\/haematol.2013.099341","article-title":"Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy","volume":"99","author":"Mateos","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.01.016_bib0074","article-title":"Real-world outcomes with cumulative bortezomib dose and efficacy in the treatment of transplant-ineligible multiple myeloma with cyclophosphamide, bortezomib, and dexamethasone","author":"Nie","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2023.01.016_bib0075","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","article-title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline","volume":"144","author":"Richardson","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.01.016_bib0076","unstructured":"BC cancer protocol summary for the treatment of multiple myeloma using bortezomib, dexamethasone with or without cyclophosphamide as induction pre-stem cell transplant Available at http:\/\/www.bccancer.bc.ca\/chemotherapy-protocols-site\/Documents\/Lymphoma-Myeloma\/MYBORPRE_Protocol.pdf Accessed: August 9, 2022])"},{"issue":"13","key":"10.1016\/j.clml.2023.01.016_bib0077","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"issue":"28","key":"10.1016\/j.clml.2023.01.016_bib0078","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2023.01.016_bib0079","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.NAJ.0000742060.56042.e7","article-title":"CE: chemotherapy-induced peripheral neuropathy","volume":"121","author":"Knoerl","year":"2021","journal-title":"Am J Nurs"},{"issue":"3","key":"10.1016\/j.clml.2023.01.016_bib0080","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00277-013-1951-6","article-title":"Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients","volume":"93","author":"K\u00f6nig","year":"2014","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.clml.2023.01.016_bib0081","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211927","article-title":"Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma","volume":"14","author":"Nahi","year":"2019","journal-title":"PLoS One"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2023.01.016_bib0082","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1182\/blood-2021-152068","article-title":"Opportunistic infections in patients receiving daratumumab regimens for multiple myeloma (MM)","volume":"138","author":"Burns","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.01.016_bib0083","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2023.01.016_bib0084","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/ejh.13374","article-title":"Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: systematic review and meta-analysis","volume":"104","author":"Mohyuddin","year":"2020","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2023.01.016_bib0085","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.01.016_bib0086","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.nut.2016.06.009","article-title":"Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma","volume":"36","author":"Kim","year":"2017","journal-title":"Nutrition"},{"issue":"15_suppl","key":"10.1016\/j.clml.2023.01.016_bib0087","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.8586","article-title":"High incidence of diarrhea in patients on long term therapy with lenalidomide and dexamethasone for multiple myeloma","volume":"26","author":"Simpson","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2023.01.016_bib0088","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.clml.2023.01.016_bib0089","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1182\/blood-2017-01-725705","article-title":"How I manage the toxicities of myeloma drugs","volume":"129","author":"Delforge","year":"2017","journal-title":"Blood"},{"issue":"3 Suppl","key":"10.1016\/j.clml.2023.01.016_bib0090","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1188\/08.CJON.S1.37-51","article-title":"Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board","volume":"12","author":"Smith","year":"2008","journal-title":"Clin J Oncol Nurs"},{"issue":"1","key":"10.1016\/j.clml.2023.01.016_bib0091","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1634\/theoncologist.11-1-51","article-title":"A practical update on the use of bortezomib in the management of multiple myeloma","volume":"11","author":"San Miguel","year":"2006","journal-title":"Oncologist"},{"issue":"14","key":"10.1016\/j.clml.2023.01.016_bib0092","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in multiple myeloma","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clml.2023.01.016_bib0093","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/NCC.0b013e3181f9904d","article-title":"Fatigue, sleep, pain, mood, and performance status in patients with multiple myeloma","volume":"34","author":"Coleman","year":"2011","journal-title":"Cancer Nurs"},{"issue":"1","key":"10.1016\/j.clml.2023.01.016_bib0094","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.12882","article-title":"A systematic review of health-related quality of life in longitudinal studies of myeloma patients","volume":"99","author":"Nielsen","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2023.01.016_bib0095","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/00013614-200604000-00009","article-title":"Recommended exercise protocol to decrease cancer-related fatigue and muscle wasting in patients with multiple myeloma: an evidence-based systematic review","volume":"22","author":"Strong","year":"2006","journal-title":"Topics Geriatric Rehabilitation"},{"issue":"2","key":"10.1016\/j.clml.2023.01.016_bib0096","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41416-020-0866-y","article-title":"Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design","volume":"123","author":"Koutoukidis","year":"2020","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.clml.2023.01.016_bib0097","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JOP.2015.006742","article-title":"Recommendations for the use of white blood cell growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"11","author":"Smith","year":"2015","journal-title":"J Oncol Pract"},{"issue":"1","key":"10.1016\/j.clml.2023.01.016_bib0098","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clml.2011.11.001","article-title":"How to manage neutropenia in multiple myeloma","volume":"12","author":"Palumbo","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.01.016_bib0099","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2147\/CLEP.S172306","article-title":"Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma","volume":"10","author":"Horv\u00e1th-Puh\u00f3","year":"2018","journal-title":"Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.clml.2023.01.016_bib0100","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/cncr.26302","article-title":"Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis","volume":"118","author":"Anaissie","year":"2012","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clml.2023.01.016_bib0101","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.21239","article-title":"Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma","volume":"83","author":"Katodritou","year":"2008","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2023.01.016_bib0102","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/s-0031-1273085","article-title":"Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis","volume":"37","author":"Zamagni","year":"2011","journal-title":"Semin Thromb Hemost"},{"issue":"9","key":"10.1016\/j.clml.2023.01.016_bib0103","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.01.016_bib0104","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s12185-020-02954-2","article-title":"Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis","volume":"112","author":"Wang","year":"2020","journal-title":"Int J Hematol"},{"issue":"9","key":"10.1016\/j.clml.2023.01.016_bib0105","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1080\/10428194.2021.1910687","article-title":"Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a post hoc analysis of phase 3 clinical trials","volume":"62","author":"Wang","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2023.01.016_bib0106","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2023.01.016_bib0107","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bjh.15392","article-title":"Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens","volume":"185","author":"Storrar","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2023.01.016_bib0108","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ajh.25459","article-title":"Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study","volume":"94","author":"Pegourie","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2023.01.016_bib0109","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjh.16653","article-title":"Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents","volume":"190","author":"Cornell","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2023.01.016_bib0110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjh.17772","article-title":"Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis","volume":"196","author":"Piedra","year":"2022","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2023.01.016_bib0111","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:01Z","timestamp":1761871321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023000356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":111,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2152265023000356"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.01.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}